Annual report pursuant to Section 13 and 15(d)

Acquisition (Tables)

v3.21.1
Acquisition (Tables)
 12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed

The reconciliation of consideration given for BioPharma to the allocation of the purchase price of assets and liabilities acquired based on their relative fair values was as follows:

 

Cash           $ 13,829  
Subordinated note payable             6,822  
Total consideration           $ 20,651  
                 
Assets acquired                
Accounts receivable           $ 3,731  
Accrued revenue             289  
Lab supplies             877  
Prepaid expenses             266  
Property and equipment             6,412  
Operating lease assets             2,187  
Acquired identifiable intangible assets:                
Trademarks and trade name     1,600          
Customer relationships     5,700          
Total acquired identifiable intangible assets             7,300  
Goodwill             8,273  
Total assets acquired             29,335  
                 
Liabilities assumed                
Accounts payable             (4,535 )
Accrued liabilities             (435 )
Deferred revenue             (1,076 )
Operating lease liabilities             (2,187 )
Finance lease liabilities             (451 )
Total liabilities assumed             (8,684 )
Net assets acquired           $ 20,651  
Schedule of ProForma Information
    Year Ended  
    December 31,  
    2019  
Revenue   $ 31,722